151 related articles for article (PubMed ID: 20079662)
1. Introduction to papers on mycoplasmology presented at a Parenteral Drug Association mycoplasma workshop.
Potts BJ
Biologicals; 2010 Mar; 38(2):181-2. PubMed ID: 20079662
[No Abstract] [Full Text] [Related]
2. Microbial identification strategies in the pharmaceutical industry.
Cundell AM
PDA J Pharm Sci Technol; 2006; 60(2):111-23. PubMed ID: 16696194
[TBL] [Abstract][Full Text] [Related]
3. The scope of mycoplasma contamination within the biopharmaceutical industry.
Armstrong SE; Mariano JA; Lundin DJ
Biologicals; 2010 Mar; 38(2):211-3. PubMed ID: 20362237
[TBL] [Abstract][Full Text] [Related]
4. Viability-based rapid microbiological methods for sterility testing and the need for identification of contamination.
Moldenhauer J
PDA J Pharm Sci Technol; 2006; 60(2):81-8. PubMed ID: 16696190
[No Abstract] [Full Text] [Related]
5. FDA's aseptic processing: proposed regulation.
Barr DB
J Parenter Sci Technol; 1993; 47(2):57-9. PubMed ID: 8515345
[No Abstract] [Full Text] [Related]
6. Rapid/automated ID methods survey. PDA Microbial ID Task Force. Parenteral Drug Association.
J Parenter Sci Technol; 1990; 44(4):216-22. PubMed ID: 2213430
[No Abstract] [Full Text] [Related]
7. Overview of the International Conference on Particle Detection, Metrology, and Control.
Knapp JZ; Barber TA
J Parenter Sci Technol; 1990; 44(5):257-63. PubMed ID: 1979082
[TBL] [Abstract][Full Text] [Related]
8. Centers for Disease Control recommendations for i.v. culturing.
Wyatt BK
Am J Hosp Pharm; 1984 Feb; 41(2):258, 262. PubMed ID: 6322582
[No Abstract] [Full Text] [Related]
9. In-process testing and limits.
Sjöholm I
Dev Biol Stand; 1997; 91():73-8. PubMed ID: 9413685
[No Abstract] [Full Text] [Related]
10. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses.
Wisher M
Cancer Gene Ther; 2002 Dec; 9(12):1056-61. PubMed ID: 12522444
[TBL] [Abstract][Full Text] [Related]
11. Depyrogenation of a parenteral solution by ultrafiltration.
Abramson D; Butler LD; Chrai S
J Parenter Sci Technol; 1981; 35(1):3-7. PubMed ID: 7229828
[No Abstract] [Full Text] [Related]
12. Current good manufacturing practice: proposed revision of certain requirements for finished pharmaceuticals; proposed rule, May 3, 1996 (61 FR 20103), [Docket No. 95N-0362]. Parenteral Drug Association.
PDA J Pharm Sci Technol; 1996; 50(6):346-51. PubMed ID: 9038078
[No Abstract] [Full Text] [Related]
13. Managing the microbiological quality of pharmaceutical excipients.
Cundell AM
PDA J Pharm Sci Technol; 2005; 59(6):381-95. PubMed ID: 16471425
[TBL] [Abstract][Full Text] [Related]
14. Technique for microbiological testing of in-use intravenous solutions and administration sets.
Lim JC
Am J Hosp Pharm; 1979 Sep; 36(9):1202-4. PubMed ID: 386787
[No Abstract] [Full Text] [Related]
15. [Possibilities of material contamination due to additional injections].
Müller-Stock A
Klin Anasthesiol Intensivther; 1977; (14):114-20. PubMed ID: 926677
[No Abstract] [Full Text] [Related]
16. [Possibilities of material contamination due to additional injections].
Mehrkens HH; Klaus E; Schmitz JE
Klin Anasthesiol Intensivther; 1977; (14):106-13. PubMed ID: 926676
[No Abstract] [Full Text] [Related]
17. PDA presentation at FDA Open Conference on Sterile Drug Manufacturing. Parenteral Drug Association.
J Pharm Sci Technol; 1994; 48(1):4-6. PubMed ID: 8004417
[No Abstract] [Full Text] [Related]
18. [Summary of the discussion on the subject of: "technical problems in the production and use of infusion solutions"].
Klin Anasthesiol Intensivther; 1977; (14):95-105. PubMed ID: 926695
[No Abstract] [Full Text] [Related]
19. [Microbiological in-process control in drug manufacture].
Seyfarth VH
Arzneimittelforschung; 1985; 35(1A):205-16. PubMed ID: 4039162
[TBL] [Abstract][Full Text] [Related]
20. Report on survey of current industry gowning practices. PDA Gowning Task Force. Parenteral Drug Association.
J Parenter Sci Technol; 1990; 44(4):223-7. PubMed ID: 2213431
[No Abstract] [Full Text] [Related]
[Next] [New Search]
